Lymphoma clinical trials in Arizona

39 actively recruiting lymphoma trials at 11 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed 2026-11-09

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Regeneron Pharmaceuticals funds and runs this clinical trial (NCT06091254). In 2024, Regeneron Pharmaceuticals reported paying the doctors leading the trial a total of $910,124 for research work on this study.

Who paid

Regeneron Pharmaceuticals, Inc. $910,124

Paid for research work on this trial

DIPENKUMAR MODI $220,976
JOSHUA BRODY(oncologist on CancerDrs) $153,783
RUEMU BIRHIRAY(oncologist on CancerDrs) $81,618
NATALIE GROVER(oncologist on CancerDrs) $60,349
EMILY AYERS(oncologist on CancerDrs) $59,405

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Grifols Therapeutics LLC funds and runs this clinical trial (NCT05645107). In 2024, Grifols Therapeutics LLC and 1 other company reported paying the doctors leading the trial a total of $77,372 for research work on this study.

Who paid

Grifols Therapeutics LLC $58,980
Grifols Biologicals LLC $18,393

Paid for research work on this trial

JOLAN WALTER $23,400
DARLA LILES(oncologist on CancerDrs) $22,780
NASHAT GABRAIL $18,958
FELIPE GASCON-RODON $5,000
TODD SHENKENBERG(oncologist on CancerDrs) $4,450

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting NIH

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06337318

Sites in Arizona:

Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Banner University Medical Center - Tucson — Tucson, Arizona
University of Arizona Cancer Center-North Campus — Tucson, Arizona